Belite Bio, Inc (BLTE) income statement
BLTENasdaqPharmaceutical PreparationsFiscal year ends December 31
$151.02−5.21 (-3.33%)
Close on Nov 19, 2026Market cap $5.94BP/E –Yield –
Belite Bio, Inc financial ratios
See a number that looks wrong?
Close on Nov 19, 2026Market cap $5.94BP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Returns on capital | |||||||
| Return on equity | -16.9% | -30.6% | -48.0% | -95.8% | 87.4% | 106.8% | – |
| Return on assets | -16.6% | -29.3% | -45.5% | -40.4% | -52.7% | – | – |
| Return on tangible assets | -16.6% | -29.3% | -45.5% | -40.4% | -52.7% | – | – |
| Return on capital employed | -18.4% | -33.7% | -47.6% | -43.5% | -58.6% | – | – |
| NOPAT | -$66.52M | -$31.60M | -$25.02M | -$10.13M | -$7.74M | -$4.54M | – |
| Cash flow quality | |||||||
| OCF / Net income | 0.48 | 0.81 | 0.94 | 0.91 | 0.77 | 0.77 | – |
| FCF / OCF | 100.2% | 100.4% | 100.2% | 103.4% | 101.0% | – | – |
| FCF / Net income | 0.48 | 0.81 | 0.95 | 0.94 | 0.78 | – | – |
| Unlevered free cash flow | -$37.06M | -$29.33M | -$29.88M | -$11.84M | -$7.55M | – | – |
| Levered free cash flow | -$37.06M | -$29.35M | -$29.90M | -$11.85M | -$7.55M | – | – |
| Efficiency | |||||||
| CapEx to OCF | -0.19% | -0.40% | -0.21% | -3.4% | -0.99% | – | – |
| Liquidity | |||||||
| Current ratio | 50.02 | 24.31 | 24.76 | 20.35 | 10.66 | – | – |
| Quick ratio | 50.02 | 24.31 | 24.76 | 20.35 | 10.66 | – | – |
| Cash ratio | 35.71 | 5.99 | 24.27 | 20.00 | 10.61 | – | – |
| Working capital | $484.39M | $141.02M | $86.31M | $40.70M | $15.80M | – | – |
| Net current asset value | $484.20M | $140.76M | $85.73M | $40.04M | $15.80M | – | – |
| Leverage | |||||||
| Assets to equity | 1.01 | 1.04 | 1.05 | 1.07 | -1.22 | – | – |
| Intangibles to total assets | 0.00% | 0.02% | – | – | – | – | – |
| Interest coverage | |||||||
| EBIT / Interest expense | -42,104.00 | -1,999.80 | -1,266.72 | -801.31 | – | -273.48 | – |
| Per share | |||||||
| EPS (basic) | -2.31 | -1.18 | -1.19 | -0.63 | -1.01 | -0.65 | – |
| EPS (diluted) | -2.31 | -1.18 | -1.19 | -0.63 | -1.01 | -0.65 | – |
| Book value per share | 19.59 | 4.58 | 3.10 | 1.67 | -1.47 | -0.80 | – |
| Tangible book value per share | 19.58 | 4.58 | 3.10 | 1.67 | -1.47 | -0.80 | – |
| Cash per share | 8.97 | 1.14 | 3.02 | 1.69 | 1.69 | 2.91 | – |
| Operating cash flow per share | -0.94 | -0.92 | -1.02 | -0.46 | -0.73 | -0.51 | – |
| Free cash flow per share | -0.94 | -0.92 | -1.03 | -0.48 | -0.73 | – | – |
| CapEx per share | 0.0018 | 0.0036 | 0.0022 | 0.02 | 0.0072 | – | – |
| Valuation at period end | |||||||
| Market cap | $5.09B | $1.84B | $1.14B | $309.72M | – | – | – |
| Enterprise value | $5.05B | $1.75B | $1.10B | $292.38M | – | – | – |
| P/B | 6.6x | 12.6x | 12.6x | 7.5x | – | – | – |
| P/TBV | 6.6x | 12.6x | 12.6x | 7.5x | – | – | – |
| P/OCF | -138x | -62.9x | -38.2x | -27.0x | – | – | – |
| EV/OCF | -137x | -59.9x | -36.8x | -25.5x | – | – | – |
| Earnings yield | -1.5% | -2.0% | -2.8% | -4.1% | – | – | – |
| FCF yield | -0.73% | -1.6% | -2.6% | -3.8% | – | – | – |
| Per employee | |||||||
| Total employees | 500 | 500 | 500 | 500 | 500 | 500 | 500 |
| Operating profit per employee | -$168.42K | -$79.99K | -$63.34K | -$25.64K | -$19.59K | -$11.49K | – |
| Net income per employee | -$155.22K | -$72.29K | -$63.26K | -$25.30K | -$19.33K | -$11.51K | – |
| Free cash flow per employee | -$74.12K | -$58.70K | -$59.80K | -$23.70K | -$15.10K | – | – |
| Growth | |||||||
| EBIT 1Y growth | -110.5% | -26.3% | -147.0% | -30.9% | -70.6% | – | – |
| Net income 1Y growth | -114.7% | -14.3% | -150.1% | -30.9% | -68.0% | – | – |
| Diluted EPS 1Y growth | -95.8% | 0.84% | -88.9% | 37.6% | -55.4% | – | – |
| Operating cash flow 1Y growth | -26.5% | 2.0% | -160.4% | -53.3% | -68.3% | – | – |
| Free cash flow 1Y growth | -26.3% | 1.8% | -152.3% | -57.0% | – | – | – |
| CapEx 1Y growth | -38.8% | 84.1% | -84.0% | 432.4% | – | – | – |
| CapEx 3Y CAGR | -43.5% | 16.2% | – | – | – | – | – |
| Total assets 1Y growth | 413.1% | 60.7% | 113.8% | 141.3% | – | – | – |
| Total assets 3Y CAGR | 160.3% | 102.4% | – | – | – | – | – |
| Total equity 1Y growth | 428.4% | 61.3% | 117.9% | 375.0% | -114.5% | -88.2% | – |
| Total equity 3Y CAGR | 164.8% | – | – | – | – | – | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.